Application of CDC25A as a targeted splicing site of SRSF10 in the preparation of drugs for the treatment of liver cancer

By discovering the SRSF10-mediated CDC25A exon 6 skip phenomenon in liver cancer cells, the expression of CDC25A (△E6) was inhibited by exon 6 of CDC25A, which solved the problem of SRSF10 on CDC25A in liver cancer treatment. The problem has significantly inhibited the proliferation and invasion ability of liver cancer cells and provided new therapeutic targets.

CN116144776BActive Publication Date: 2024-11-22THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211623876.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-14
Publication Date
2024-11-22
Estimated Expiration
2042-12-14

AI Technical Summary

Technical Problem

In the current stage of liver cancer treatment, the effect of SRSF10 on variable shearing of CDC25A has not been clarified, and the mechanism affecting the cell cycle of liver cancer has not been fully explored, resulting in poor therapeutic effect of liver cancer.

Method used

CDC25A exon 6 skip reading phenomenon was found in liver cancer cells through SRSF10 overexpression, which confirmed that exon 6 of CDC25A is a targeted shear site for SRSF10, and inhibitors of exon 6 of CDC25A (such as shRNA) were used to inhibit CDC25A. The expression of (△E6) in turn affects its protein activity and cell cycle regulation.

Benefits of technology

It effectively inhibits the expression and pro-cancer effects of CDC25A (△E6), weakens the proliferation and invasion ability of liver cancer cells, provides a new targeted treatment mechanism for liver cancer, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003998559540000011
    Figure HDA0003998559540000011
  • Figure HDA0003998559540000021
    Figure HDA0003998559540000021
  • Figure HDA0003998559540000031
    Figure HDA0003998559540000031
Patent Text Reader

Abstract

The research of the present invention shows that exon 6 of CDC25A can be used as a targeted splicing site of SRSF10. Specifically, the main mRNA isoforms of CDC25A are the longer isoform CDC25A (L) containing exon 6 and the shorter isoform CDC25A (△E6) not containing exon 6; SRSF10 activates the skipping of exon 6 of CDC25A, resulting in a significant increase in the expression of CDC25A (△E6) isoform mRNA; the experiment further confirms that CDC25A (△E6) has better stability and more nuclear distribution than CDC25A (L). In short, SRSF10 can activate the production of splicing variant CDC25A (△E6) with a more pro-cancer effect, and play a role in promoting the occurrence and development of liver cancer. The applicant has confirmed for the first time that exon 6 of CDC25A can be used as a targeted splicing site of SRSF10, providing a new direction for targeted liver cancer therapeutic drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of cell cycle regulatory protein CDC25A as a SRSF10 targeted splicing site in the preparation of liver cancer therapeutic drugs. Background Art

[0002] Primary liver cancer is one of the most common malignant tumors in the world, with the incidence ranking fifth among all cancers and the mortality ranking second among all cancers. Radical resection of liver cancer is currently the main treatment for liver cancer. Because liver cancer is relatively hidden in its onset, easy to metastasize, easy to recur, and has a high mortality rate, the treatment effect of liver cancer is still not satisfactory, and the prognosis of patients is still not ideal. It is particularly important to explore the factors and mechanisms related to the occurrence and development of liver cancer; it can not only help patients with early diagnosis and bring new options for the treatment of liver cancer, but also may bring better prognosis to patients.

[0003] Alternative splicing is a key post-transcriptional gene expression regulation method that helps expand the complexity of protein types and regulate mRNA metabolism. Precursor mRNA (pre-mRNA) transcribed from the same gene can form different splicing isoforms through alternative splicing, and finally form different proteins to play different functions. At present, many studies are devoted to the mechanism of alternative splicing of target genes. Studies have reported that alternative splicing of mRNA can change the diversity of proteomes in various tumors. Abnormal alternative splicing is involved in the regulation of tumor cell proliferation and metastasis, and plays an important role in tumor occurrence, development, drug treatment and drug resistance. Serine / arginine splicing factor 10 (SRSF10) is a member of the mammalian splicing regulator family SR protein. Like other SR proteins, SRSF10 protein consists of an RNA binding domain (RRM) and an auxiliary domain (RS) rich in arginine and serine, which guides the interaction with other proteins. The phosphorylation state of SRSF 10 is crucial for its activity and changes during mitosis, heat shock and DNA damage. By controlling the alternative splicing of specific transcripts, overexpression of SRSF10 plays a promoting role in an increasing number of cancers. The splicing factor SRSF10 was first identified as a factor with inhibitory splicing activity and was later shown to also produce positive splicing effects. Increased SRSF10 expression is often observed in tumors. As a potential cell cycle and mitosis indicator, it has broad clinical application prospects such as tumor monitoring.

[0004] As an important member of the CDC25 family, CDC25A is a dual-specific protein phosphatase that can hydrolyze tyrosine and serine / threonine to dephosphorylate them. CDC25A plays an important role in cell cycle regulation. CDC25A can activate the Cyclin-CDK complex, thereby promoting the transformation of the G1 / S phase and the G2 / M phase, and is an important target for DNA damage response. CDC25A has the characteristics of a proto-oncogene and is currently a potential target for a variety of malignant tumors. CDC25A is highly expressed in liver cancer tissues, and its expression level is significantly positively correlated with portal vein metastasis of liver cancer. At the same time, proliferating cell nuclear antigen (PCNA) in liver cancer is also positively correlated with CDC25A expression, which increases with the increase of its expression, leading to enhanced proliferation of liver cancer cells and tumor development. However, there is no report on the effect of CDC25A variable splicing on its expression and protein activity.

[0005] At present, the role of SRSF10 in liver cancer is still unclear, and there is no literature reporting the effect of SRSF10 on the alternative splicing of CDC25A on the cell cycle of liver cancer cells. Summary of the invention

[0006] This study aims to provide a new SRSF10-CDC25A alternative splicing target that is closely related to the occurrence and development of liver cancer. In the present invention, we overexpressed SRSF10 in liver cancer cells HepG2 and Hep3B, and used a series of tests such as RNA-seq to find the phenomenon of cell cycle regulatory gene CDC25A exon 6 skipping. In vivo and in vitro experiments further confirmed that SRSF10-mediated CDC25A exon 6 skipping can produce CDC25A (△E6) with higher stability and protein activity, which is closely related to the K150 ubiquitination site, K169 ubiquitination site and S178 phosphorylation site on exon 6.

[0007] The technical solution of the present invention is:

[0008] Application of inhibitors of exon 6 of CDC25A as targeted splicing agents of SRSF10 in the preparation of drugs for the treatment of liver cancer.

[0009] Furthermore, the inhibitor of exon 6 of CDC25A is one or more of an inhibitor of CDC25A (L) and an inhibitor of CDC25A (△E6).

[0010] Furthermore, the inhibitor of exon 6 of CDC25A is shRNA of CDC25A.

[0011] Furthermore, exon 6 of CDC25A was used as a targeted splicing site for SRSF10.

[0012] The present invention will be further explained and illustrated below:

[0013] Our study found that the splicing factor SRSF10 is highly expressed in liver cancer and can promote the occurrence and development of liver cancer by regulating the alternative splicing of CDC25A. Specifically, the main mRNA isoforms of CDC25A are the longer isoform CDC25A (L) containing exon 6 and the shorter isoform CDC25A (△E6) not containing exon 6; SRSF10 activates the skipping of exon 6 of CDC25A, resulting in a significant increase in the expression of CDC25A (△E6) isoform mRNA; the experiment further confirmed that CDC25A (△E6) has better stability and more nuclear distribution than CDC25A (L), because the amino acid sequence corresponding to exon 6 has two ubiquitination sites, lysine 150 (K150) and lysine 169 (K169), and a phosphorylation site, serine 178 (S178), so that more CDC25A (△E6) enters the cell nucleus, avoids degradation, and plays a greater role in cell cycle regulation. In summary, SRSF10 can activate the production of a splice variant CDC25A (△E6) with a more pro-oncogenic effect, thereby promoting the occurrence and development of liver cancer. The applicants have confirmed for the first time that exon 6 of CDC25A can serve as a targeted splicing site for SRSF10, which may play an important role in the study of the mechanism of targeted treatment of liver cancer.

[0014] We found that the immunohistochemical score of SRSF10 in liver cancer tissues was significantly higher than that in the corresponding adjacent tissues, and SRSF10 promoted the proliferation, cycle and invasion of liver cancer cells. We further found that SRSF10 led to an increase in the shorter isoform CDC25A (△E6) that does not contain exon 6, while the expression of CDC25A (L) was reduced, and there was protein-mRNA binding between SRSF10 RRM and CDC25A exon6 fragments. The above together confirmed that SRSF10 recognizes and regulates the variable splicing of CDC25A exon6.

[0015] As the two most common isoforms of CDC25A, CDC25A(△E6) in liver cancer tissues was significantly higher than that in the corresponding adjacent tissues, while CDC25A(L) expression was significantly decreased. The ability of CDC25A(△E6) to promote cell proliferation, cycle, and invasion was shown to be significantly stronger than that of CDC25A(L).

[0016] To explain the stronger tumor-promoting ability of CDC25A(△E6), we predicted that the amino acid sequence corresponding to CDC25A exon 6 contained two ubiquitination sites (K150, K169) and one phosphorylation site (S178) ( Figure 4A). The ubiquitination level of endogenous CDC25A(L) is higher than that of CDC25A(△E6), which may be the reason why CDC25A(L) is easily degraded ( Figure 4 C). CDC25A(L) protein is localized in the cytoplasm, while the vast majority of CDC25A(△E6) is localized in the nucleus, further confirming that CDC25A(L) is easily degraded by ubiquitin-proteasome in the cytoplasm. After single-site or double-site mutation of K150 and K169 in CDC25A(L) exon 6, the ubiquitination level of CDC25A decreased significantly, while the expression of CDC25A(△E6) was significantly increased. Immunofluorescence confirmed that CDC25A tended to transfer into the nucleus after mutation of the ubiquitination site. Therefore, K150 and K169 mutations can increase the stability of CDC25A protein. The above experimental results illustrate that ubiquitination at the K150 and K169 sites in CDC25A exon 6 is an important mechanism for the decrease of its stability.

[0017] We then verified that SRSF10 overexpression can lead to CDC25A dephosphorylation, especially a significant decrease in the phosphorylation level at Ser178, which in turn promotes cell cycle-related proteins. By constructing dephosphorylation mutant CDC25A-S178A and persistent phosphorylation mutant CDC25A-S178E plasmids, we found that phosphorylation at Ser178 did not affect CDC25A protein stability, but increased the distribution of cytoplasmic CDC25A. This confirms that SRSF10-mediated dephosphorylation of CDC25A Ser178 can activate its protein activity by promoting CDC25A nuclear translocation.

[0018] We further constructed cell models with silenced expression of CDC25A(△E6), CDC25A(L), and CDC25A(FL), and found that when SRSF10 was overexpressed, silencing the expression of CDC25A(△E6) and CDC25A(FL) could completely inhibit cell proliferation, cell cycle, and invasion, while silencing the expression of CDC25A(L) only partially inhibited the proliferation, cell cycle, and invasion of liver cancer cells, confirming that CDC25A(△E6) exerted the main pro-cancer biological effect of SRSF10-mediated CDC25A. In animal tumor formation experiments, we confirmed that SRSF10 promoted the growth of transplanted tumors, while silencing CDC25A(△E6) could inhibit proliferation. Finally, we verified that CDC25A(△E6) and CDC25A(L) had the same effects on transplanted tumor growth and downstream molecules as in in vitro experiments ( Figure 8 C, 8D). This confirms that SRSF10 plays a decisive role in CDC25A exon 6 skipping and activates SRSF10-mediated tumor-promoting effects.

[0019] In summary, the present invention confirms that SRSF10 plays an oncogene role in liver cancer, and induces CDC25A exon 6 skipping, positively regulating the expression of the isomer CDC25A (△E6); CDC25A (△E6) shows less ubiquitination and phosphorylation tendency, thereby protecting CDC25A protein from ubiquitin-proteasome degradation; more CDC25A (△E6) enters the nucleus and plays a pro-cancer role. The present invention confirms for the first time that CDC25A exon 6 is the target site of SRSF10 variable splicing, and for the first time finds that protecting the K150 site and K169 site on exon 6 from ubiquitination modification may improve the stability of CDC25A protein and increase protein activity. It was found that protecting the S178 site on exon 6 from phosphorylation can increase the nuclear distribution of CDC25A protein and increase protein activity. Based on the mechanism by which SRSF10 recognizes and regulates skipping of CDC25A exon 6, the three ubiquitination and phosphorylation modification sites located in CDC25A exon 6 are very valuable potential therapeutic targets for liver cancer drugs. Therefore, CDC25A, as a variable splicing site targeted by SRSF10, may become a new therapeutic target for improving the treatment and survival of patients with liver cancer or other cancers. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Figure 1 shows that SRSF10 is highly expressed in liver cancer and is positively correlated with the malignant phenotype of liver cancer. AB: Western blot and immunohistochemistry were used to determine the expression of SRSF10 in 50 clinical cancer tissues and paracancerous tissues. Statistical analysis of immunohistochemical evaluation values ​​was performed, and representative images (Case 1-10) were selected. It was found that the expression of SRSF10 protein and immunohistochemical scores in liver cancer tissues were significantly higher than those in the corresponding paracancerous tissues (p<0.001, χ2 test). CF: CCK-8, EdU, flow cytometry and Transwell assays were used to detect the effects of SRSF10 on the proliferation, cycle and invasion of liver cancer cells. Overexpression of SRSF10 in Hep3B and HepG2 cells significantly accelerated cell proliferation and invasion, and the proportion of cells in the S and M phases increased significantly (p<0.001). After silencing SRSF10, cell proliferation, cycle and invasion were significantly inhibited (p<0.001). The bar graph data of each group are the average values ​​of three independent repeated experiments.

[0021] Figure 2Figure 2 shows that SRSF10 recognizes and regulates the alternative splicing of CDC25A exon6. A: Transcriptome microarray confirmed that when SRSF10 was silenced, the alternative splicing event of CDC25A exon skipping was weakened (q<0.001). B: Primer design for the longer isoform CDC25A(L) retaining exon 6, the shorter isoform CDC25A(△E6) not containing exon 6, the mRNA fragment containing exon 5, and the mRNA fragment containing exon 7. CD: semi-RT-PCR and Western blotting confirmed that when SRSF10 was overexpressed, CDC25A(△E6) increased, while CDC25A(L) expression decreased; compared with the SRSF10(WT) overexpression group, CDC25A(△E6) did not increase when SRSF10(△RRM) lacking the RRM binding domain was overexpressed. E: CLIP-qPCR assay and Flag-western blotting experiments confirmed that SRSF10 containing the RRM binding domain can activate the skipping of exon 6, but has no effect on exon 5 and exon 7 on both sides.

[0022] Figure 3 It is a figure showing that CDC25A (△E6) is highly expressed in liver cancer and has a higher cancer-promoting phenotype. A: semi-RT-PCR measured the expression levels of CDC25A (△E6) and CDC25A (L) in 10 clinical cancer tissues and adjacent tissues. It was found that CDC25A (△E6) in liver cancer tissues was significantly higher than that in the corresponding adjacent tissues, while CDC25A (L) expression was significantly decreased. BF: A liver cancer cell model containing only exogenous CDC25A (L) or CDC25A (△E6) was successfully constructed, and it was found that CDC25A (△E6) was significantly stronger than CDC25A (L) in promoting cell proliferation, cycle, and invasion. The bar graph data of each group are the average of three independent repeated experiments, **p < 0.01, ***p < 0.001.

[0023] Figure 4This is a diagram showing that exon 6 downregulates protein stability by activating ubiquitination and nucleocytoplasmic shuttling of CDC25A protein. A: The amino acid sequence corresponding to CDC25A exon 6 is predicted to have two ubiquitination sites and one phosphorylation site. B: SRSF10 can lead to increased ubiquitination of CDC25A. C: Immunoprecipitation and Western blotting revealed that the ubiquitination level of endogenous CDC25A(L) is higher than that of CDC25A(△E6). DE: Immunofluorescence and cell fractionation experiments confirmed that CDC25A(L) protein is localized in the cytoplasm, while the vast majority of CDC25A(△E6) is localized in the nucleus. F: CHX+MG132 experiments confirmed that CDC25A(△E6) has better protein stability than CDC25A(L).

[0024] Figure 5 This is a diagram showing that ubiquitination at K150 and K169 sites in CDC25A exon 6 is an important mechanism for its decreased stability. A: Western blot and immunoprecipitation were used to detect the effects of ubiquitination modification at K150 and K169 sites in CDC25A (L) on the fate of CDC25A protein. After single or double mutations at K150 and K169, the ubiquitination level of CDC25A decreased significantly, and the expression of CDC25A (△E6) was significantly increased. B: Immunofluorescence detection of single / double mutations at K150 and K169 showed that CDC25A tended to transfer into the nucleus. C: CHX experiments confirmed that mutations at K150 and K169 can increase the stability of CDC25A protein.

[0025] Figure 6This is a diagram showing that SRSF10 activates the dephosphorylation of CDC25A Ser178. A: Dephosphorylation of CDC25A Ser178 can activate the activity of CDC25A protein. Rabusertib, as a highly selective inhibitor of the key cell cycle regulatory protein CHK1, can inhibit the phosphorylation of CDC25A protein. Overexpression of SRSF10 can lead to dephosphorylation of CDC25A, especially a significant decrease in the phosphorylation level at Ser178, promote the expression of cell cycle-related proteins (CDK2, p-CDK2, CDK6, p-CDK6) and inhibit the expression of apoptosis-related molecules (BCL-2, p-BCL-2). BC: Phosphorylation at Ser178 does not affect the stability of CDC25A protein, but can increase the distribution of cytoplasmic CDC25A. Dephosphorylation mutation CDC25A-S178A and persistent phosphorylation mutation CDC25A-S178E were successfully constructed, and CHX+MG132 experiments confirmed that there was no difference in the protein stability of CDC25A (WT), CDC25A-S178A, and CDC25A-S178E. Immunofluorescence showed that in the dephosphorylation mutation CDC25A-S178A model, the fluorescence intensity of CDC25A in the nucleus was significantly increased, while in the persistent phosphorylation mutation CDC25A-S178E model, the fluorescence was mainly in the cytoplasm. DG: Dephosphorylation mutation can significantly enhance the proliferation, cycle, and invasion ability of liver cancer cells. The bar graph data of each group are the average of three independent repeated experiments, **p<0.01, ***p<0.001.

[0026] Figure 7 Figure 2 shows the decisive role of SRSF10 in regulating the skipping of CDC25A exon 6 in vitro. AC: semi-RT-PCR results confirmed the silencing expression model of CDC25A (△E6), CDC25A (L), and CDC25A (FL). DG: Under the condition of SRSF10 overexpression, silencing expression of CDC25A (△E6) and CDC25A (FL) can completely inhibit cell proliferation, cell cycle, and invasion ability, while silencing expression of CDC25A (L) only partially inhibits the proliferation, cell cycle, and invasion ability of liver cancer cells, confirming that CDC25A (△E6) plays the main cancer-promoting biological effect of CDC25A mediated by SRSF10. The bar graph data of each group are the average of three independent repeated experiments, **p < 0.01, ***p < 0.001.

[0027] Figure 8This is a diagram showing the decisive role of SRSF10 in the regulation of CDC25A exon 6 skipping in tumor formation experiments. AB: It is confirmed that SRSF10 promotes the growth of transplanted tumors, while silencing CDC25A (△E6) can inhibit proliferation. Immunohistochemistry was used to detect the expression of CDC25A and p-CDC25A (S178) in transplanted tumors. CD: It is confirmed that exogenous CDC25A (△E6) and CDC25A (L) have the same effects on transplanted tumor growth and downstream molecules as in vitro experiments. DETAILED DESCRIPTION

[0028] The present invention is further explained and illustrated below in conjunction with the accompanying drawings and experimental data.

[0029] Materials and Methods

[0030] Cell culture and transfection, qRT-PCR analysis, western blot analysis, immunohistochemistry assay, MTT assay, flow cytometry, immunoprecipitation, chromatin immunoprecipitation, immunofluorescence, dual luciferase assay, and flow cytometry assay for Lipid-ROS are all existing methods and will not be described here.

[0031] The specific sequences of the shRNAs for the full-length CDC25A, CDC25A (L), and CDC25A (ΔE6) in the examples are as follows:

[0032] CDC25A(FL)-shRNA-1:TAGACGTCCTCCGTCCATATC (SEQ ID NO.1)

[0033] CDC25A(FL)-shRNA-2:TCAACTTCATCAATCACTTTA (SEQ ID NO.2)

[0034] CDC25A(L)-shRNA-1:GAGTTTAAGAAGCCAGTAAGACC (SEQ ID NO.3)

[0035] CDC25A(L)-shRNA-2:GGGTAAAGATCTCTTCACACAGA (SEQ ID NO.4)

[0036] CDC25A(△E6)-shRNA-1:ACAAGGAAAATCTTTCCTCAAAT (SEQ ID NO.5)

[0037] CDC25A(△E6)-shRNA-2:GAACAAGGAAAATCTTTCCTCAA (SEQ ID NO.6)

[0038] 2. Results

[0039] 2.1 SRSF10 is highly expressed in liver cancer tissues and can cause the cell cycle molecule CDC25A exon 6 to skip

[0040] We first used immunohistochemistry and Western blot to measure the expression of SRSF10 in 50 clinical cancer tissues and adjacent tissues. We found that the immunohistochemical score of SRSF10 in liver cancer tissues was significantly higher than that in the corresponding adjacent tissues ( Figure 1 A, 1B). Cell experiments confirmed that SRSF10 promotes the proliferation, cycle and invasion of liver cancer cells ( Figure 1 C, 1D, 1E, 1F). Transcriptome microarray confirmed that when SRSF10 was silenced, the alternative splicing event of CDC25A exon skipping was weakened ( Figure 2 A). We constructed an SRSF10 overexpression plasmid, and semi-RT-PCR and Western blotting confirmed that SRSF10 caused an increase in the shorter isoform CDC25A (△E6) that does not contain exon 6, while reducing the expression of CDC25A (L) ( Figure 2 B, 2C); further constructing the SRSF10 (△RRM) overexpression plasmid lacking the RRM binding domain, semi-RT-PCR, CLIP-qPCR assay and Flag-western blotting confirmed the protein-mRNA binding between SRSF10 RRM and CDC25Aexon6 fragment ( Figure 2 The above data confirm that SRSF10 recognizes and regulates the alternative splicing of CDC25A exon6.

[0041] △E6) has a stronger ability to promote cancer than CDC25A(L)

[0042] To further explore the mechanism by which SRSF10 promotes the occurrence and development of liver cancer by increasing CDC25A(△E6), we found that CDC25A(△E6) in liver cancer tissues was significantly higher than that in the corresponding adjacent tissues, while CDC25A(L) expression was significantly decreased ( Figure 3 A). The in vitro model successfully constructed a liver cancer cell model containing only exogenous CDC25A(L) or CDC25A(△E6), and found that CDC25A(△E6) was significantly more capable of promoting cell proliferation, cell cycle, and invasion than CDC25A(L) ( Figure 3 B, 3C, 3D, 3E, 3F).

[0043] Ubiquitination of K150 and K169 sites on the cytoplasm is an important reason for the decrease in protein stability

[0044] In order to explain the stronger cancer-promoting ability of CDC25A(△E6), we first started from the protein stability level and predicted that the amino acid sequence corresponding to CDC25A exon 6 had two ubiquitination sites (K150, K169) and one phosphorylation site (S178) ( Figure 4 A). We found that SRSF10 can lead to increased ubiquitination of CDC25A ( Figure 4 B) Simultaneous immunoprecipitation and Western blotting revealed that the ubiquitination level of endogenous CDC25A(L) was higher than that of CDC25A(△E6), which may be the reason why CDC25A(L) is easily degraded ( Figure 4 C). Through immunofluorescence and cell fractionation experiments, we found that CDC25A(L) protein is localized in the cytoplasm, while most CDC25A(△E6) is localized in the nucleus. This also confirms from another perspective that CDC25A(L) is easily degraded by ubiquitin-proteasome in the cytoplasm ( Figure 4 D, 4E). We used CHX+MG132 experiments to confirm that CDC25A(△E6) has better protein stability than CDC25A(L) ( Figure 4 F). We performed point mutations on the ubiquitination sites K150 and K169 in CDC25A(L) exon 6 and found that after single or double mutations at K150 and K169, the ubiquitination level of CDC25A was significantly decreased, and at the same time, the expression of CDC25A(△E6) was significantly increased ( Figure 5 A), and immunofluorescence confirmed that CDC25A tended to be transferred into the nucleus after the ubiquitination site mutation ( Figure 5 B). CHX experiments found that K150 and K169 mutations can increase the stability of CDC25A protein ( Figure 5 C). The above experimental results illustrate that ubiquitination at K150 and K169 sites in CDC25A exon 6 is an important mechanism for its decreased stability

[0045] 2.4 SRSF10 activates the dephosphorylation of CDC25A Ser178, promotes CDC25A nuclear translocation and activates protein activity

[0046] We first used Rabusertib, a highly selective inhibitor of the key cell cycle regulatory protein CHK1, to confirm that it can inhibit the phosphorylation of CDC25A protein. Overexpression of SRSF10 can lead to dephosphorylation of CDC25A, especially a significant decrease in the phosphorylation level of Ser178 site, promote the expression of cell cycle-related proteins (CDK2, p-CDK2, CDK6, p-CDK6) and inhibit the expression of apoptosis-related molecules (BCL-2, p-BCL-2). ( Figure 6A). By constructing the dephosphorylation mutant CDC25A-S178A and the persistent phosphorylation mutant CDC25A-S178E plasmids, we found that phosphorylation at Ser178 did not affect the stability of CDC25A protein, but increased the distribution of CDC25A in the cytoplasm ( Figure 6 B, 6C). Dephosphorylation mutations can significantly enhance the proliferation, cycle, and invasion of liver cancer cells ( Figure 6 This confirms that SRSF10-mediated dephosphorylation of CDC25A Ser178 can activate its protein activity by promoting CDC25A nuclear translocation.

[0047] Plays a decisive role in CDC25A exon 6 skipping

[0048] We further constructed cell models with silent expression of CDC25A(△E6), CDC25A(L), and CDC25A(FL) ( Figure 7 A, 7B, 7C), found that under the condition of SRSF10 overexpression, silencing the expression of CDC25A (△E6) and CDC25A (FL) can completely inhibit cell proliferation, cell cycle, and invasion ability, while silencing the expression of CDC25A (L) only partially inhibits the proliferation, cell cycle, and invasion ability of liver cancer cells, confirming that CDC25A (△E6) plays the main cancer-promoting biological effect of SRSF10-mediated CDC25A ( Figure 7 D, 7E, 7F, 7G). In animal tumorigenesis experiments, we confirmed that SRSF10 promoted the growth of transplanted tumors, while silencing CDC25A (△E6) inhibited proliferation ( Figure 8 A, 8B). We finally verified that CDC25A(△E6) and CDC25A(L) had the same effects on transplanted tumor growth and downstream molecules as in in vitro experiments ( Figure 8 C, 8D).

[0049] In summary, the present invention confirms that SRSF10 plays an oncogene role in liver cancer, and induces CDC25A exon 6 skipping, positively regulating the expression of the isomer CDC25A (△E6); CDC25A (△E6) shows less ubiquitination and phosphorylation tendency, thereby protecting CDC25A protein from ubiquitin-proteasome degradation; more CDC25A (△E6) enters the nucleus and plays a pro-cancer role. The present invention confirms for the first time that CDC25A exon 6 is the target site of SRSF10 variable splicing, and for the first time finds that protecting the K150 site and K169 site on exon 6 from ubiquitination modification may improve the stability of CDC25A protein and increase protein activity. It was found that protecting the S178 site on exon 6 from phosphorylation can increase the nuclear distribution of CDC25A protein and increase protein activity. Based on the mechanism by which SRSF10 recognizes and regulates the skipping of CDC25A exon 6, the three ubiquitination and phosphorylation modification sites located on CDC25A exon 6 are very valuable potential therapeutic targets for liver cancer drugs. Therefore, CDC25A, as a variable splicing site targeted by SRSF10, may become a new therapeutic target for improving the treatment and survival of patients with liver cancer or other cancers.

Claims

1. Use of an inhibitor of exon 6 of CDC25A as a targeted cleavage reagent of SRSF10 in the preparation of a drug for treating liver cancer, wherein the inhibitor of exon 6 of CDC25A is shRNA of CDC25A, and the shRNA of CDC25A is shown in SEQ ID NO.5-SEQ ID NO.6.